Top 10 pharma R&D budgets in 2018Amazing what TLT did with its tiny 50M$ R&D budget since 2010 when compared with these Goliaths of R&D budgets. And we have "
investors" that take the time to post here that they will vote "no" to options to TLT's management. ... lollll
Despite all these mega R&D budgets, none of these big pharmas have destroyed solid tumors in a way that comes close to ours. Not even close. Mostly shrinkage of tumors, at best, with efficacy ratios of around 20-25% and high toxicity.
The top 10 pharma R&D budgets in 2018
1. Roche ... (11.0B$/year)
2. Johnson & Johnson ... (10.8B$/year)
3. Merck & Co. ... (9.7B$/year)
4. Novartis ... (9.0B$/year)
5. Pfizer ... (8.0B$/year)
6. Sanofi ... (6.9B$/year)
7. Bristol-Myers Squibb ... (6.3B$/year)
8. AstraZeneca ... (5.9B$/year)
9. Eli Lilly ... (5.3B$/year)
10. GlaxoSmithKline ... (5.2B$/year)
The report says that the “importance of large pharma in originating molecules is decreasing,” but they “remain important partners” for biotech. Still, they see the need for smaller biopharmas to team up with Big Pharma companies—and their large sales teams—decreasing.
“The dynamics of development, M&A and licensing activity seem to be shifting, and emerging companies are retaining control of their assets to a greater degree,” the report's authors wrote.
Coupled with this is the fact that, according to the index, emerging biopharma companies (those spending less than $200 million annually on R&D and having less than $500 million in sales) account for 72% of all late-stage pipeline activity, up from 61% a decade ago.
Roche, J&J, Novartis and the like are still the unmatched big boys when it comes to R&D budgets, with Roche once again coming out on top with a staggering $11 billion in R&D spend last year (though this also includes its diagnostics business).